Published in Blood on February 04, 2009
Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nat Biotechnol (2015) 2.20
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood (2010) 2.06
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect. Cell (2015) 1.94
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol (2013) 1.88
Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia. Biol Blood Marrow Transplant (2011) 1.47
Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica (2009) 1.38
Antibody-based immunotherapy of cancer. Cell (2012) 1.35
Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood (2010) 1.17
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica (2012) 1.09
The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas. Clin Cancer Res (2015) 0.98
γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody. Haematologica (2010) 0.89
Follicular lymphoma tumor-infiltrating T-helper (T(H)) cells have the same polyfunctional potential as normal nodal T(H) cells despite skewed differentiation. Blood (2011) 0.87
Therapeutic antibodies against cancer. Hematol Oncol Clin North Am (2012) 0.87
Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma. Cancer Sci (2014) 0.85
An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions. MAbs (2015) 0.85
EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects. Cancers (Basel) (2011) 0.85
Enhancement of Immune Effector Functions by Modulating IgG's Intrinsic Affinity for Target Antigen. PLoS One (2016) 0.84
Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice. Leukemia (2014) 0.83
Entourage: the immune microenvironment following follicular lymphoma. Blood Cancer J (2012) 0.83
Immunotherapy for B-cell lymphoma: current status and prospective advances. Front Immunol (2012) 0.82
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer (2016) 0.81
A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma. J Immunother (2013) 0.80
Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions. MAbs (2011) 0.80
Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. MAbs (2012) 0.80
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clin Cancer Res (2016) 0.80
CD137 stimulation enhances the vaccinal effect of anti-tumor antibodies. Oncoimmunology (2014) 0.79
Signaling by Antibodies: Recent Progress. Annu Rev Immunol (2017) 0.76
Obinutuzumab for relapsed or refractory indolent non-Hodgkin's lymphomas. Ther Adv Hematol (2016) 0.76
A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses. J Biol Chem (2016) 0.76
A TLR7 agonist enhances the anti-tumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells. Leukemia (2016) 0.76
Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients. Clin Dev Immunol (2013) 0.76
Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma. Oncotarget (2015) 0.76
CTLA-4 Limits Anti-CD20-Mediated Tumor Regression. Clin Cancer Res (2016) 0.75
The Roles of Radiotherapy and Immunotherapy for the Treatment of Lymphoma. Mol Cell Pharmacol (2013) 0.75
Human Cytokine Genetic Variants Associated With HBsAg Reverse Seroconversion in Rituximab-Treated Non-Hodgkin Lymphoma Patients. Medicine (Baltimore) (2016) 0.75
Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse? Front Immunol (2015) 0.75
The Role and Function of Fcγ Receptors on Myeloid Cells. Microbiol Spectr (2016) 0.75
Fcγ Receptor Function and the Design of Vaccination Strategies. Immunity (2017) 0.75
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (1998) 9.77
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol (2007) 8.31
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 6.47
Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med (2000) 5.62
Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med (1998) 5.59
Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol (1997) 5.48
Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods (1996) 4.87
From the bench to the bedside: ways to improve rituximab efficacy. Blood (2004) 3.15
Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood (2000) 2.64
Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med (2002) 2.54
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood (2001) 2.53
Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest (2002) 2.13
Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol (2006) 1.69
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood (2002) 1.66
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother (2000) 1.60
Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res (2006) 1.58
Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis (2000) 1.55
Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25- and CD4+CD25- T cells. J Immunol (2007) 1.33
Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol (2000) 1.28
Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res (2000) 1.14
Germ line tumor-associated immunoglobulin VH region peptides provoke a tumor-specific immune response without altering the response potential of normal B cells. Blood (2004) 0.85
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07
Revised response criteria for malignant lymphoma. J Clin Oncol (2007) 22.19
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature (2010) 8.78
Oncogenically active MYD88 mutations in human lymphoma. Nature (2010) 7.34
Follicular lymphoma international prognostic index. Blood (2004) 7.20
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol (2006) 7.14
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol (2014) 6.61
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science (2008) 6.52
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell (2003) 6.11
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol (2014) 6.10
Molecular diagnosis of Burkitt's lymphoma. N Engl J Med (2006) 6.10
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med (2003) 6.06
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A (2008) 5.90
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol (2006) 4.87
Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med (2013) 4.49
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature (2012) 4.33
Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood (2010) 4.28
Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron (2004) 4.21
T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine. J Immunol (2006) 3.40
B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum (2004) 3.35
The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci U S A (2006) 3.30
Critical assessment of automated flow cytometry data analysis techniques. Nat Methods (2013) 3.30
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood (2005) 3.12
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol (2003) 3.00
The epidemiology of non-Hodgkin's lymphoma. Oncogene (2004) 2.71
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood (2013) 2.65
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood (2006) 2.63
Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol (2013) 2.46
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol (2006) 2.38
Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A (2010) 2.34
Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group. J Clin Oncol (2008) 2.11
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol (2004) 2.08
A clustered plasticity model of long-term memory engrams. Nat Rev Neurosci (2006) 2.06
Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol (2006) 2.03
The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum (2003) 2.02
Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol (2007) 1.94
Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med (2007) 1.94
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist (2007) 1.93
Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood (2002) 1.90
Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Cancer Biol Ther (2009) 1.88
Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J Virol (2010) 1.80
Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol (2005) 1.78
Simulation and prediction of the adaptive immune response to influenza A virus infection. J Virol (2009) 1.76
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood (2013) 1.72
CpG DNA activation and plasma-cell differentiation of CD27- naive human B cells. Blood (2006) 1.65
Cutting edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo. J Immunol (2003) 1.62
High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma (2012) 1.62
Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood (2007) 1.60
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol (2009) 1.57
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol (2008) 1.56
Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood (2012) 1.49
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood (2010) 1.48
High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era. Leuk Lymphoma (2011) 1.46
Breast lymphoma associated with breast implants: two case-reports and a review of the literature. Leuk Lymphoma (2002) 1.46
Amphiregulin, a TH2 cytokine enhancing resistance to nematodes. Science (2006) 1.44
Cutting edge: CD4+ T cell-derived IL-2 is essential for help-dependent primary CD8+ T cell responses. J Immunol (2008) 1.37
Tsx produces a long noncoding RNA and has general functions in the germline, stem cells, and brain. PLoS Genet (2011) 1.37
Burkitt lymphoma in adults. Hematology Am Soc Hematol Educ Program (2008) 1.35
B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol (2006) 1.34
Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25- and CD4+CD25- T cells. J Immunol (2007) 1.33
Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS One (2011) 1.33
Interleukin (IL)-1A and IL-6: applications to the predictive diagnostic testing of radiation pneumonitis. Int J Radiat Oncol Biol Phys (2005) 1.30
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood (2007) 1.29
Activated human B lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production. J Immunol (2005) 1.28
A presenilin-1 mutation identified in familial Alzheimer disease with cotton wool plaques causes a nearly complete loss of gamma-secretase activity. J Biol Chem (2010) 1.28
Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol (2012) 1.28
Protein vaccines induce uncommitted IL-2-secreting human and mouse CD4 T cells, whereas infections induce more IFN-gamma-secreting cells. J Immunol (2006) 1.26
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br J Haematol (2013) 1.25
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood (2011) 1.25
Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice. J Immunol (2008) 1.24
Modulation of single-cell IgG secretion frequency and rates in human memory B cells by CpG DNA, CD40L, IL-21, and cell division. J Immunol (2009) 1.22
More than structural cells, fibroblasts create and orchestrate the tumor microenvironment. Immunol Invest (2006) 1.21
Diffuse large B-cell lymphoma. Hematol Oncol Clin North Am (2008) 1.21
Non-Hodgkin's lymphomas, version 4.2014. J Natl Compr Canc Netw (2014) 1.17
Measuring the frequency of mouse and human cytotoxic T cells by the Lysispot assay: independent regulation of cytokine secretion and short-term killing. Nat Med (2003) 1.17
Late residual gamma-H2AX foci in murine skin are dose responsive and predict radiosensitivity in vivo. Radiat Res (2010) 1.17
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol (2012) 1.17
Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma. Clin Cancer Res (2012) 1.17
Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer (2012) 1.16
Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab. Haematologica (2008) 1.16
Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network. J Clin Oncol (2008) 1.15